ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

ClinicalTrials.gov ID: NCT02748135

Public ClinicalTrials.gov record NCT02748135. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma

Study identification

NCT ID
NCT02748135
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Oncurious NV
Industry
Enrollment
18 participants

Conditions and interventions

Interventions

  • TB-403 100mg/kg Drug
  • TB-403 175mg/kg Drug
  • TB-403 20mg/kg Drug
  • TB-403 50mg/kg Drug

Drug

Eligibility (public fields only)

Age range
6 Months to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2016
Primary completion
Oct 5, 2020
Completion
Oct 5, 2020
Last update posted
Jan 12, 2021

2016 – 2020

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Not listed Little Rock Arkansas 72202
Not listed Oakland California 94609
Not listed Hartford Connecticut 06106
Not listed Boston Massachusetts 02115
Not listed Grand Rapids Michigan 49503
Not listed St Louis Missouri 63104
Not listed Hackensack New Jersey 07601
Not listed Charleston South Carolina 29425
Not listed Austin Texas 78723
Not listed Dallas Texas 75235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02748135, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2021 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02748135 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →